<!-- page 1 -->

# **NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE** 

# **HEALTH TECHNOLOGY APPRAISAL PROGRAMME Equality impact assessment – Guidance development** 

# **STA Mepolizumab for treating severe refractory eosinophilic asthma** 

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme. 

## **Consultation** 

1. Have the potential equality issues identified during the scoping process been addressed by the Committee, and, if so, how? 

   - access to tertiary care centres, and 

   - identifying all appropriate patients (who may not present with typical symptoms). 

2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the Committee addressed these? 

Neither of these issues represents a potential equality issue that could be addressed by the Committee. Access to tertiary care is an implementation issue and identifying appropriate patients is a clinical issue. 

3. Have any other potential equality issues been identified by the Committee, and, if so, how has the Committee addressed these? 

No other potential equality issues were identified by the Committee. 

Technology appraisals: Guidance development Equality impact assessment for the single technology appraisal of mepolizumab for treating severe refractory eosinophilic asthma Issue date: November 2016 

1 of 6 



<!-- page 2 -->

4. Do the preliminary recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group? 

No 

5. Is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability? 

No 

6. Are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE’s obligations to promote equality? 

No 

7. Have the Committee’s considerations of equality issues been described in the appraisal consultation document, and, if so, where? 

Not applicable 

## **Approved by Associate Director (name):** Melinda Goodall 

**Date:** 23/09/15 

## **Second consultation** 

Technology appraisals: Guidance development Equality impact assessment for the single technology appraisal of mepolizumab for treating severe refractory eosinophilic asthma Issue date: November 2016 

2 of 6 



<!-- page 3 -->

1. Have any additional potential equality issues been raised during the consultation, and, if so, how has the Committee addressed these? 

The company stated that the age used in the company’s model was based on the trial and representative of English clinical practice. The company stated that “non-guidance on the basis that a small number of patients at either extreme of the age distribution may be less cost effective runs the risk of depriving the target population we believe would be inequitable.” 

The committee did not consider this to be an equalities issue. The committee noted that the population in England is likely to be younger than the trial population, and also noted that exploring this had a marginal impact on results. 

No other potential equality issues were identified. 

2. If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group? 

## N/A 

3. If the recommendations have changed after consultation, is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability? 

## N/A 

4. If the recommendations have changed after consultation, are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 2 and 3, or otherwise fulfil NICE’s obligations to promote equality? 

Technology appraisals: Guidance development 

Equality impact assessment for the single technology appraisal of mepolizumab for treating severe refractory eosinophilic asthma Issue date: November 2016 

3 of 6 



<!-- page 4 -->

## N/A 

5. Have the Committee’s considerations of equality issues been described in the final appraisal determination, and, if so, where? 

The summary table notes that no equalities issues were identified. 

## **Approved by Associate Director (name):** Melinda Goodall 

**Date:** 31/05/2016 

Technology appraisals: Guidance development Equality impact assessment for the single technology appraisal of mepolizumab for treating severe refractory eosinophilic asthma Issue date: November 2016 

4 of 6 



<!-- page 5 -->

## **Final Appraisal Determination** 

1. Have the potential equality issues identified during the scoping process been addressed by the Committee, and, if so, how? 

- No potential equality issues were identified. 

2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the Committee addressed these? 

N/A 

3. Have any other potential equality issues been identified by the Committee, and, if so, how has the Committee addressed these? 

## N/A 

4. Do the recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group? 

N/A 

5. Is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability? 

## N/A 

Technology appraisals: Guidance development Equality impact assessment for the single technology appraisal of mepolizumab for treating severe refractory eosinophilic asthma Issue date: November 2016 

5 of 6 



<!-- page 6 -->

|6.|Are there any recommendations or explanations that the Committee|
|---|---|
||could make to remove or alleviate barriers to, or difficulties with,|
||access identified in questions 4 or 5, or otherwise fulfil NICE’s|
||obligations to promote equality?|
|N/A||
|||
|7.|Have the Committee’s considerations of equality issues been|
||described in the final appraisal determination, and, if so, where?|
|The|summary table notes that no equalities issues were identified|



## **Approved by Programme Director (name):** …M. Boysen………………… 

**Date:** 23/11/2016 

Technology appraisals: Guidance development Equality impact assessment for the single technology appraisal of mepolizumab for treating severe refractory eosinophilic asthma Issue date: November 2016 

6 of 6 

